NFKB1 and B-cell chronic lymphocytic leukemia: NF‐κB activity normally correlates with chemoresistance and poorer clinical outcome.14, 15, 16 CUDC‐907 can inhibit NF‐κB signalling and thus reduce the protection that it exerts on CLL cells, which will decrease cell resistance and promote spontaneous or drug‐mediated apoptosis.